EUCTR2010-022229-13-IT进行中（未招募）不适用
A Randomized, Double-Blind, Placebo-Controlled, Study of the Safety and Efficacy of Farletuzumab in combination with Carboplatin and Paclitaxel or Docetaxel Followed by Pemetrexed in Chemotherapy na?ve Subjects with Stage IV Adenocarcinoma of the Lung with Wild Type EGFR - MORAb-003-009
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 165
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •[1] Female or male and =18 years of age [2] Histologically or cytologically confirmed adenocarcinoma of the lung classified as stage IV [3] Wild-type EGFR [4] Adenocarcinoma of the lung must have confirmation of folate receptor-alpha (FRA) expression in =5% of tumor cells by immunohistochemistry [5] Measurable disease with at least one unidimensionally measurable lesion according to RECIST criteria version 1.1 by CT or MRI scans (CT or MRI scans must have been performed within 30 days prior to the first dose of farletuzumab or placebo) [6] Must have received no prior chemotherapy, radiation therapy or surgery with curative intent for adenocarcinoma of the lung [7] ECOG performance status (0 or 1) [8] Life expectancy of =3 months as estimated by the investigator [9] Adequate bone marrow reserve and organ function including calculated creatinine clearance =60 mL/min based on the standard Cockcroft-Gault equation [10] Other significant medical conditions must be well-controlled and stable in the opinion of the investigator for at least 30 days prior to the first dose of farletuzumab or placebo [11] Laboratory and clinical results within 14 days prior to Day 1 must be as follows: Absolute neutrophil count = 1.5 x 10^9/L; Platelet count = 100 x 10^9/L Hemoglobin =9 g/dL; Serum bilirubin = 1.5 x ULN; AST/ALT/ALK-P = 2.0 x ULN; Serum creatinine =2.0 mg/ dL [12] Subjects of childbearing potential must be surgically sterile or consent to use a medically acceptable method of contraception throughout the study period (Contraceptive measures must start either prior to or at screening and continue throughout the entire study period and for 2 months after the last dose of study drug is administered; Pregnant and/or lactating females are excluded) [13] Subject must provide written informed consent and must be able to comply with the protocol procedures
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •[1] Subjects who have had previous chemotherapy for adenocarcinoma of the lung [2] Prior surgery with curative intent for adenocarcinoma of the lung XML File Identifier : 5lWStsxaE99yG+Xao+NN2C/Lvms= [3] Prior radiotherapy for adenocarcinoma of the lung. (Prior treatment with local radiotherapy for symptom control [i.e., palliative radiation with non-curative intent] is permitted) [4] EGFR mutation (exon 19 deletion and exon 21 activating mutation L858R) by IHC as assessed by the central laboratory or by PCR assessed by the investigative site [5] Clinically significant cardiovascular disease, congestive heart failure (New York Heart Association Class 3 or 4), clinically significant ventricular arrhythmia requiring medication, or unstable angina within 6 months of study enrolment [6] ECG demonstrating clinically significant arrhythmias (Note: subjects with chronic atrial arrhythmia, i.e. atrial fibrillation or paroxysmal supraventricular tachycardia [SVT] are eligible) [7] Peripheral neuropathy = NCI CTCAE v 3.0 Grade 2 [8] Known untreated brain metastases (Subjects with previously treated, stable brain metastases are allowed. Per investigator’s discretion subject must have fully recovered from radiotherapy or surgery (minimum of 14 days) prior to study entry; steroid or other anti-convulsant treatment must be completed 14 days prior to study entry) [9] Unable or unwilling to take folic acid, vitamin B12, or corticosteroids [10] Concurrent immunotherapy (i.e., immunosuppressants or chronic use of systemic steroids with the exception of low-dose corticosteroids) [11] Known allergic reaction to a prior monoclonal antibody therapy or have any documented HAHA [12] Previous treatment with farletuzumab [13] Active serious systemic disease, including active bacterial or fungal infection [14] Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, psychiatric illness, or social situations that would limit compliance with study requirements [15] Known active human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C infection (Asymptomatic positive serology is not exclusionary) [16] Evidence of other active invasive malignancy requiring treatment in the past 5 years [17] Prior treatment with any investigational agent within 4 weeks of study entry [18] Breast-feeding, pregnant, or likely to become pregnant during the study
研究者
相似试验
招募中
3 期
A study to test Taldefgropeb Alfa in patients with Spinal Muscular Atrophy.Spinal Muscular Atrophy2024-511852-42-00Biohaven Pharmaceuticals Inc.104
进行中（未招募）
1 期
A study to test Taldefgropeb Alfa in patients with Spinal Muscular Atrophy.Spinal Muscular AtrophyMedDRA version: 20.1Level: PTClassification code: 10041582Term: Spinal muscular atrophy Class: 100000004850CTIS2024-511852-42-00Biohaven Pharmaceuticals Inc.169
进行中（未招募）
1 期
Study of the Neurokinin-1 Receptor Antagonist VPD-737 in Subjects with Prurigo NodularisEUCTR2013-005024-42-DEMenlo Therapeutics, Inc.140
尚未招募
2 期
To evaluate the efficacy of nasal oxytocin in the treatment of migraine headachesmigraine headacheNeurological - Other neurological disordersACTRN12607000384459Trigemina, Inc100
进行中（未招募）
1 期
Study of the Neurokinin-1 Receptor Antagonist VPD-737 in Subjects with Prurigo NodularisPruritus nodularisMedDRA version: 18.0Level: LLTClassification code 10037084Term: Prurigo nodularisSystem Organ Class: 100000004858EUCTR2013-005024-42-IETigercat Pharma, Inc.140